Loading...

STORM-PE Trial And New Therapies Will Expand Global Reach

Published
27 Aug 24
Updated
08 Sep 25
AnalystConsensusTarget's Fair Value
US$303.33
15.7% undervalued intrinsic discount
10 Sep
US$255.61
Loading
1Y
34.0%
7D
1.6%

Author's Valuation

US$303.3315.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on08 Sep 25
Fair value Decreased 2.22%

The reduction in Penumbra’s Analyst Price Target reflects a combination of weakening net profit margins and a higher future P/E multiple, with fair value revised down from $310.24 to $303.33. What's in the News Company completed repurchase of 517,763 shares (1.33%) for $100 million under the current buyback, with no shares repurchased in the latest quarter.

Shared on07 May 25
Fair value Decreased 1.06%

Shared on30 Apr 25
Fair value Increased 2.00%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 1.62%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 0.44%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 3.24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 3.14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Decreased 1.51%